{"entity":{"id":"nct07393282","kind":"trial","name":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","aka":["LINKER-SMM2"],"tldr":"A phase 3 trial of Linvoseltamab, Daratumumab in multiple myeloma, run by Regeneron Pharmaceuticals, now recruiting.","summary":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) is a phase 3 interventional study registered as NCT07393282 by Regeneron Pharmaceuticals, with 270 participants planned, started 2026-05-21 and due to reach its primary completion in 2033-07-27. Interventions recorded: Linvoseltamab, Daratumumab. Conditions listed: High Risk Smoldering Multiple Myeloma (HR-SMM). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07393282","url":"https://clinicaltrials.gov/study/NCT07393282"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","smouldering-myeloma"],"sections":[],"technologies":["monoclonal-antibody","t-cell-engager"],"targets":[],"drugs":["linvoseltamab","daratumumab"],"companies":["regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07393282","phase":"3","setting":"A Phase 3, Randomized, Open-Label Study of Linvoseltamab Versus Daratumumab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma","sponsor":"Regeneron Pharmaceuticals","started":"2026-05-21","startedType":"actual","enrolled":270,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07393282/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"smouldering-myeloma","kind":"cancer","name":"Smouldering multiple myeloma","route":"/cancers/smouldering-myeloma/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/"},{"id":"linvoseltamab","kind":"drug","name":"Linvoseltamab","route":"/drugs/linvoseltamab/"}],"company":[{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}]}}